Pulse Biosciences, Inc. Announces Positive Clinical Data for nPulse™ System in Benign Thyroid Nodule Ablation
Hayward, CA, March 9, 2026 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, has released new clinical data demonstrating highly favorable outcomes for its proprietary nPulse™ System in the ablation of benign thyroid nodules. This development marks a potentially significant milestone in the company’s trajectory and may have material implications for investors and the company’s share price.
Key Highlights from the Report
- 100% Patient-Reported Cosmetic Satisfaction: All patients in the study were “Highly Satisfied” with the cosmetic results at the final follow-up.
- 95% Patient-Reported Overall Satisfaction: An overwhelming majority of patients (95%) reported being “Highly Satisfied” with their overall treatment outcome at the final follow-up.
- No Serious Adverse Events: The study reported zero serious adverse events, suggesting a favorable safety profile for the nPulse™ System.
- No Intranodular Fibrosis Detected: Ultrasound assessments conducted between 15-22 months post-procedure showed no evidence of intranodular fibrosis, a critical concern in thyroid ablation procedures.
- Potential for Clinical Durability: The absence of intranodular fibrosis and the high satisfaction rates hint at the potential for long-term durability and effectiveness of the treatment.
Details for Shareholders and Potential Price-Sensitive Information
- First-of-Its-Kind Study: The clinical data on benign thyroid nodule ablation positions Pulse Biosciences at the forefront of non-thermal ablation technology. The nPulse™ System utilizes nanosecond pulses of electrical energy to clear targeted cells while sparing adjacent non-cellular tissue, differentiating it from thermal ablation techniques.
- Market Expansion Potential: The company is actively developing the nPulse™ technology not only for thyroid nodules but also for the treatment of atrial fibrillation and other soft tissue ablation markets. This diversification could open significant new revenue streams if clinical success translates into regulatory approval and commercial adoption.
- Competitive Advantage: The nPulse™ System’s ability to deliver non-thermal ablation with high satisfaction and safety may give Pulse Biosciences a strong competitive position versus traditional thermal ablation and surgical options.
- No Indication of FDA Approval Yet: While the results are positive, investors should note that the report does not mention regulatory approval for commercial use in the U.S or elsewhere. The news relates to clinical data, which, although promising, is an early step towards market adoption.
- Press Release and Further Communication: The company has issued a press release (Exhibit 99.1) to publicize these results, signaling its intent to communicate the significance of this data to the market and stakeholders.
About Pulse Biosciences, Inc.
Pulse Biosciences is committed to health innovation through bioelectric medicine. The company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear targeted cells. The company is developing nPulse for use in atrial fibrillation and other surgical soft tissue ablation indications, aiming to improve patient outcomes and provider workflows. The company owns several trademarks, including nPulse™, Vybrance™, CellFX™, Nano-Pulse Stimulation™, NPS™, nsPFA™, and others.
Forward-Looking Statements
Pulse Biosciences has cautioned that any statements regarding early clinical successes, future regulatory approval, commercialization, or competitive position are forward-looking and subject to risks and uncertainties. The company reminds investors that actual outcomes may differ materially from current expectations and that there is no guarantee of future regulatory approval or market adoption. Investors are urged to review the company’s filings with the SEC for further information on these risks.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The forward-looking statements herein are based on current information and expectations, which are subject to change without notice.
View PULSE BIOSCIENCES, INC. Historical chart here
